Clearmind posts positive early trial results

Clearmind Medicine Inc. filed a Form 6-K to furnish a press release announcing positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder.

Rhea-AI Filing Summary

Clearmind Medicine Inc. filed a Form 6-K to furnish a press release announcing positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder. The filing states that the first three paragraphs of this press release are incorporated by reference into the company’s existing shelf and equity compensation registration statements on Forms F-3 and S-8, making the clinical update part of those offerings’ disclosed information.

Insights

Biotech and clinical-stage equities analyst

Clearmind highlights positive initial data from an early alcohol use disorder trial.

The company reports positive top-line results from the first cohort of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. While the excerpt does not detail efficacy or safety metrics, simply stating “positive” results at this stage signals that the study has progressed to a point where initial data are viewed favorably enough to disclose to investors.

The company also incorporates the first three paragraphs of the press release into its existing Form F-3 and Form S-8 registration statements. This step ensures that investors relying on those registration documents have access to the same clinical update, aligning capital markets disclosures with the development status of the program.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine Inc. (CMND) report in this Form 6-K?

Clearmind Medicine Inc. furnished a press release announcing positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder.

Which clinical program is mentioned for Clearmind Medicine Inc. (CMND)?

The Form 6-K references an FDA-approved Phase I/IIa clinical trial for alcohol use disorder, for which Clearmind reported positive top-line results from the first cohort.

How is the press release used in Clearmind Medicine Inc.’s (CMND) registration statements?

The first three paragraphs of the press release are incorporated by reference into Clearmind’s registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).

Why is incorporation by reference mentioned in Clearmind Medicine Inc.’s (CMND) filing?

Incorporation by reference means the key parts of the press release become part of the disclosure record for Clearmind’s existing F-3 and S-8 registration statements, keeping those documents current with the clinical update.

Who signed the Form 6-K for Clearmind Medicine Inc. (CMND)?

The Form 6-K was signed on behalf of Clearmind Medicine Inc. by Adi Zuloff-Shani, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:16 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on November 18, 2025, titled “Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder”.

The first three paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: November 18, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3